Kura Oncology (NASDAQ:KURA) Announces Quarterly Earnings Results, Beats Estimates By $0.04 EPS

Kura Oncology (NASDAQ:KURA) issued its quarterly earnings data on Tuesday. The company reported ($0.78) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.82) by $0.04, FiscalAI reports. The firm had revenue of $22.84 million during the quarter, compared to analysts’ expectations of $24.94 million. Kura Oncology had a negative net margin of 384.30% and a negative return on equity of 207.18%.

Kura Oncology Price Performance

Shares of Kura Oncology stock remained flat at $7.57 on Tuesday. 2,464,364 shares of the stock traded hands, compared to its average volume of 1,722,917. The company has a fifty day simple moving average of $10.60 and a 200-day simple moving average of $9.79. The company has a debt-to-equity ratio of 0.12, a current ratio of 4.73 and a quick ratio of 4.71. Kura Oncology has a 12 month low of $6.75 and a 12 month high of $13.90. The company has a market capitalization of $673.43 million, a price-to-earnings ratio of -2.25 and a beta of 0.56.

Insider Buying and Selling at Kura Oncology

In related news, SVP Thomas Doyle sold 4,607 shares of the business’s stock in a transaction on Monday, September 28th. The shares were sold at an average price of $10.50, for a total value of $48,373.50. Following the sale, the senior vice president directly owned 142,428 shares of the company’s stock, valued at approximately $1,495,494. The trade was a 3.13% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, COO Kathleen Ford sold 3,668 shares of the business’s stock in a transaction on Tuesday, September 29th. The shares were sold at an average price of $10.75, for a total transaction of $39,431.00. Following the completion of the sale, the chief operating officer directly owned 142,986 shares in the company, valued at $1,537,099.50. This represents a 2.50% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 153,881 shares of company stock valued at $1,708,183 over the last quarter. 7.60% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several analysts recently commented on the company. Citizens Jmp reaffirmed a “market outperform” rating and set a $24.00 price objective on shares of Kura Oncology in a research note on Monday, August 24th. Cantor Fitzgerald reissued an “overweight” rating on shares of Kura Oncology in a research note on Wednesday, October 14th. JPMorgan Chase & Co. began coverage on Kura Oncology in a report on Thursday, October 1st. They issued an “overweight” rating and a $30.00 price target for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Kura Oncology in a report on Thursday, October 15th. Finally, Citigroup reaffirmed a “market outperform” rating on shares of Kura Oncology in a research report on Wednesday, October 14th. Eleven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $25.35.

Kura Oncology Company Profile

Kura Oncology is a biopharmaceutical company focused on developing precision medicines for cancer. Its research has centered on therapies that target molecular pathways involved in tumor growth and blood cancers. The company’s best-known program is ziftomenib, an oral menin inhibitor developed for acute myeloid leukemia, including forms associated with NPM1 mutations or KMT2A rearrangements. Kura has also worked on other targeted cancer therapies. Based in San Diego, California, Kura conducts drug development and clinical research in the United States and has worked with international partners to advance its programs.